DE60336588D1 - Verbesserte anthraximpfstoffe und abgabeverfahren - Google Patents

Verbesserte anthraximpfstoffe und abgabeverfahren

Info

Publication number
DE60336588D1
DE60336588D1 DE60336588T DE60336588T DE60336588D1 DE 60336588 D1 DE60336588 D1 DE 60336588D1 DE 60336588 T DE60336588 T DE 60336588T DE 60336588 T DE60336588 T DE 60336588T DE 60336588 D1 DE60336588 D1 DE 60336588D1
Authority
DE
Germany
Prior art keywords
delivery
anthraximp
improved
anthrax
vaccines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60336588T
Other languages
English (en)
Inventor
John A Mikszta
Vincent J Sullivan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DICKINSON AND CO
Original Assignee
DICKINSON AND CO
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DICKINSON AND CO filed Critical DICKINSON AND CO
Application granted granted Critical
Publication of DE60336588D1 publication Critical patent/DE60336588D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/07—Bacillus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
DE60336588T 2003-02-13 2003-08-13 Verbesserte anthraximpfstoffe und abgabeverfahren Expired - Lifetime DE60336588D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US44699503P 2003-02-13 2003-02-13
US48646003P 2003-07-14 2003-07-14
PCT/US2003/025158 WO2004073735A1 (en) 2003-02-13 2003-08-13 Improved anthrax vaccines and delivery methods

Publications (1)

Publication Number Publication Date
DE60336588D1 true DE60336588D1 (de) 2011-05-12

Family

ID=32912248

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60336588T Expired - Lifetime DE60336588D1 (de) 2003-02-13 2003-08-13 Verbesserte anthraximpfstoffe und abgabeverfahren

Country Status (7)

Country Link
US (1) US20070154494A1 (de)
EP (1) EP1592443B1 (de)
JP (1) JP2006517913A (de)
AT (1) ATE503491T1 (de)
AU (1) AU2003255275A1 (de)
DE (1) DE60336588D1 (de)
WO (1) WO2004073735A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1735338B1 (de) 2004-02-11 2013-04-24 Ligocyte Pharmaceuticals, Inc. Anthrax-antigene und anwendungsverfahren
GB0607462D0 (en) * 2006-04-13 2006-05-24 Avecia Ltd Assay
US20080226729A1 (en) * 2006-09-08 2008-09-18 Becton, Dickinson And Company Stable powder formulations of alum-adsorbed vaccines
EP1972347A1 (de) * 2007-03-19 2008-09-24 Becton, Dickinson and Company, Wagner, Jaconda Stabile Impfstoffpulverformulierungen
AU2008263970B2 (en) * 2007-06-14 2014-01-30 Crucell Switzerland Ag Intradermal influenza vaccine
CA2716399C (en) 2008-03-05 2020-07-21 Pierre Chouvenc Process for stabilizing an adjuvant containing vaccine composition
WO2010038076A1 (en) 2008-10-02 2010-04-08 Pharmathene Uk Limited Anthrax vaccine formulation and uses thereof
US20100183675A1 (en) * 2009-01-22 2010-07-22 Allan Watkinson Stable vaccine compositions and methods of use
JP2012515752A (ja) * 2009-01-22 2012-07-12 ファーマシーネ，インコーポレイテッド 安定なワクチン組成物とその使用方法
GB201007207D0 (en) * 2010-04-29 2010-06-16 Univ Cork Method
WO2013139384A1 (en) * 2012-03-21 2013-09-26 Dorkoosh, Farid Abedin Freezing of aerosolized solutions (fas): a system for continuous particle production
CN110227152A (zh) * 2012-04-23 2019-09-13 巴拉特生物技术国际有限公司 轮状病毒疫苗组合物及其制备方法
JP6028063B2 (ja) * 2015-04-30 2016-11-16 ナノメド ディヴァイシーズ， インコーポレイテッド アプリケータに統合可能な内蔵非言語的指示デバイス
EP3669929A4 (de) * 2017-08-17 2021-05-12 Cosmed Pharmaceutical Co., Ltd. Mikronadelfeld für lippen

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7012832A (de) * 1970-08-29 1972-03-02
US5840312A (en) * 1991-05-02 1998-11-24 Institut Pasteur Recombinant Bacillus anthracis strains unable to produce the lethal factor protein or edema factor protein
JP2930526B2 (ja) * 1994-05-31 1999-08-03 株式会社キートロン インジェクター型アトマイザー
US6316006B1 (en) * 1994-11-23 2001-11-13 The United States Of America As Represented By The Secretary Of The Army Asporogenic B anthracis expression system
US6348450B1 (en) * 1997-08-13 2002-02-19 The Uab Research Foundation Noninvasive genetic immunization, expression products therefrom and uses thereof
US6284282B1 (en) * 1998-04-29 2001-09-04 Genentech, Inc. Method of spray freeze drying proteins for pharmaceutical administration
US6770479B1 (en) * 1998-07-10 2004-08-03 The United States Of America As Represented By The Secretary Of The Army Anthrax vaccine
US6329156B1 (en) * 1999-03-22 2001-12-11 The Regents Of The University Of California Method for screening inhibitors of the toxicity of Bacillus anthracis
FR2798291B1 (fr) * 1999-09-10 2005-01-14 Pasteur Institut Compositions acellulaires immunogenes et compositions acellulaires vaccinales contre bacillus anthracis
US6835184B1 (en) * 1999-09-24 2004-12-28 Becton, Dickinson And Company Method and device for abrading skin
US6595947B1 (en) * 2000-05-22 2003-07-22 Becton, Dickinson And Company Topical delivery of vaccines
WO2002100340A2 (en) * 2001-06-08 2002-12-19 Avant Immunotherapeutics, Inc. Improved vaccination against anthrax
BR0210628A (pt) * 2001-06-29 2004-08-10 Becton Dickinson Co Liberação intradérmica de vacinas e agentes terapêuticos genéticos via microcânula
BR0214279A (pt) * 2001-11-19 2005-12-20 Becton Dickinson Co Composições farmacêuticas em forma particulada

Also Published As

Publication number Publication date
AU2003255275A1 (en) 2004-09-09
JP2006517913A (ja) 2006-08-03
WO2004073735A1 (en) 2004-09-02
US20070154494A1 (en) 2007-07-05
ATE503491T1 (de) 2011-04-15
EP1592443A4 (de) 2007-02-21
EP1592443B1 (de) 2011-03-30
EP1592443A1 (de) 2005-11-09

Similar Documents

Publication Publication Date Title
CY1122681T1 (el) Απο του στοματος σκευασματα αναλογων κυτιδινης και μεθοδοι χρησης αυτων
WO2007024941A3 (en) Polyvalent vaccine
PH12014501836A1 (en) Novel adjuvant compositions
DE60336588D1 (de) Verbesserte anthraximpfstoffe und abgabeverfahren
MX2011006205A (es) Proteinas f del vrs modificadas y metodos de uso de las mismas.
UA99659C2 (uk) Мультивалентна вакцина з нативних везикул зовнішньої мембрани менінгококів, способи її застосування
MX2007010996A (es) Nuevas composiciones de liposomas.
TW200716646A (en) (S)-N-methylnaltrexone
TW200740458A (en) Vaccination against dengue virus infection
MX2012000035A (es) Antigenos de virus de sincicio respiratorio recombinantes.
MY129263A (en) Vaccine composition
MX2009004862A (es) Estabilizacion de vacunas por liofilizacion.
GB0109297D0 (en) Vaccine
GB2386072A (en) Novel vaccine
WO2009009759A3 (en) Yersinia pestis antigens, vaccine compositions, and related methods
MX349119B (es) Vacuna de virus de dengue inactivado.
HK1097774A1 (en) Stable pharmaceutical composition comprising linezolid from iv
CR9246A (es) Formulaciones terapeuticas del factor de crecimiento de queratinocitos
WO2010053610A3 (en) Stable anthrax vaccine formulations
CY1112575T1 (el) Βελτιωμενα αδρανοποιημενα εμβολια fcv
DE69922804D1 (de) Verwendung von polymeren der hyaluronsäure zur mukosalen freigabe von impfstoffen und adjuvantien
WO2007028985A3 (en) Adjuvanted vaccine
DE602005021873D1 (de) Neues impfstoffadjuvans und dessen herstellung und verwendung
EA200701201A1 (ru) Новая фармацевтическая композиция для вакцин
DK1604683T3 (da) Gangliogsid-baserede vaccinesammensætninger til subkutan administration